The Serum amyloid A (SAA) ELISA is an enzyme immunoassay for the quantitative determination of Serum amyloid A (SAA) in human serum, plasma, and other body fluids.
The microtiter plate is coated with the antibody specifically binding the Serum amyloid A (SAA1 and SAA2). The human serum or plasma is incubated in the plate with the capture antibody. The specimen is washed out and the specifically bound protein is incubated with biotin-labelled detection antibody. Following another washing step, Streptavidin-HRP conjugate is added into the well. Unbound reagent is then washed out. Horseradish peroxidase (HRP) bound in the complex reacts with the chromogenic substrate (TMB) creating the blue colour. The reaction is stopped by addition of STOP solution (H2SO4). The absorbance values are measured at 450 nm (optionally 450/630 nm) and are proportional to the concentration of SAA in the specimen. The concentration of SAA in unknown samples is determined from the calibration curve which is created by plotting the absorbance values against the standard concentration values.
Catalog No:BA1006
Regular price
$560.00 USD
Regular price
$560.00 USD
Sale price
$560.00 USD
Unit price/ per
Sale
Sold out
2 weeks
Couldn't load pickup availability
Product Details
Species ReactivityHuman
Sensitivity1.56 ng/mL
Detection Range6.25 - 200 ng/mL
Sample TypeSerum, Plasma
Sample Size5 uL
Incubation(s)3 hour(s)
Research AreasInflammation
BackgroundSerum amyloid A (SAA) is a highly sensitive acute phase reactant that has been linked to inflammatory diseases, both infectious and non-infectious origin. SAA is an apolipoprotein that interacts with HDL, promotes the accumulation of leukocytes at the site of inflammation and the adhesion of platelets, and participates in the removal of damaged cell membranes. The acute phase SAAs (SAA1, SAA2) are transcriptionally regulated in hepatocytes by a variety of inflammatory cytokines, and they can transiently increase > 1000-fold. The combination of SAA, PCT, and CRP can improve the differential diagnosis of early bacterial and viral infections. Several studies indicated that SAA allows monitoring of disease activity in various inflammatory rheumatic diseases and autoinflammatory diseases, including SLE, amyloidosis, or rheumatoid arthritis. SAA can be also used to risk prediction of coronary heart disease, the prognosis of tumour patients, and observation of transplant rejection.
